Gilead's Kite recruits an AbbVie/NIH veteran to head up cell therapy R&D. And he's taking aim at AML in a ferociously competitive field
Four months after Kite R&D exec Peter Emtage jumped ship to sign on with Versant as a CEO-in-waiting, the big Gilead sub has recruited immuno-oncology expert Francesco Marincola to take his place as head of cell therapy research — putting him in a prominent position in a booming field.
Marincola has been making the rounds to a certain extent as cell therapy took hold as one of the hottest fields in drug R&D. He made his rep at the NIH — where he spent 23 years, 15 as head of the Infectious Disease and Immunogenetics Section at the NIH Clinical Center — and then jumped to AbbVie, where he guided I/O discovery strategy. The research exec spent close to 3 years in his last post as CSO at Refuge Biotechnologies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.